Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bone Markers for Early Detection of Bone Metastases in Prostate Cancer
NCT00391690Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2006
- Primary completion
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in bone metastases, sponsored by Novartis. Primary endpoint: Relationship between change in bone parameters and bone scan with respect to bone metastases. Started Feb 2006; status: completed.
02
Drugs
zoledronic acid
03
Conditions
bone metastases
Beyond the preview
Go deeper on NCT00391690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391690.